Dissolution kinetics of propranolol hydrochloride 40 mg tablets under biowaiver conditions
Authors:
- Lennin R. Rodriguez-SaavedraLRLennin R. Rodriguez-Saavedra
- Pedro M. Alva-PlasenciaPAPedro M. Alva-Plasencia
- Yuri F. Curo-VallejosYCYuri F. Curo-Vallejos
- Segundo F. Saavedra-SuárezSSSegundo F. Saavedra-Suárez
- Luis A. Chávez-AbantoLCLuis A. Chávez-Abanto
- Olga E. Caballero-AquiñoOCOlga E. Caballero-Aquiño
- Miriam E. Gutiérrez-RamosMGMiriam E. Gutiérrez-Ramos
- Junior F. Sánchez-BautistaJSJunior F. Sánchez-Bautista
- 1 September 2024
- journal article
- research article
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 12 (5) , 814-821
Abstract
Context: Ensuring the quality of a generic drug is essential for its commercialization. Propranolol hydrochloride is a drug in great demand on the market as it is widely used as an antihypertensive, antianginal, antiarrhythmic, and for the treatment of migraine, requiring a complete evaluation to determine equivalence. Aims: To evaluate the dissolution biopharmaceutical characteristic in multisource products marketed in the Peruvian market, taking Inderal® as a reference product. Methods: In vitro conditions are simulated using the USP apparatus II at 50 rpm and 900 mL of the dissolution media pH 1.2, 4.5, and 6.8 at 37°C. The dependent mathematical models were characterized by the Akaike information criterion, and the similarity was evaluated using the independent parameters (MDT, DE, and the similarity factor f2). Results: The average dissolution percentages demonstrate a difference between the multisource and the innovator in the three-dissolution media. The model that best characterizes the dissolution kinetics in all products is that of Hixson–Crowell. A significant difference was obtained in the MDT and DE between the innovative and multisource products and in the three-dissolution media. The similarity factor was not within the acceptable range for multisource products in the three-dissolution media. Conclusions: The 40 mg propranolol hydrochloride tablets included in the study are not equivalent in vitro to the innovative product and, therefore, are not interchangeable.Keywords
This publication has 9 references indexed in Scilit:
- Dissolution Testing in Drug Product Development: Workshop Summary ReportThe AAPS Journal, 2019
- The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual frameworkJournal of Market Access & Health Policy, 2019
- A Comparative Study of Propranolol Release by In Vitro Dissolution Profiles in Pharmaceutical FormulationsDissolution Technologies, 2018
- Dissolution Efficiency and Design Space for an Oral Pharmaceutical Product in Tablet FormIndustrial & Engineering Chemistry Research, 2015
- Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalenceEuropean Journal of Pharmaceutical Sciences, 2014
- Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial ViewThe AAPS Journal, 2008
- Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenololJournal of Pharmaceutical Sciences, 2004
- Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methodsInternational Journal of Pharmaceutics, 2000
- In vitro ? In vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical exampleEuropean Journal of Clinical Pharmacology, 1985